A prospective open label single center non-interventional study assessing effectiveness and safety of the Alirocumab and Evolocumab in patients treated in lipid clinics in Germany
Latest Information Update: 16 Mar 2021
At a glance
- Drugs Alirocumab (Primary) ; Evolocumab (Primary)
- Indications Hypercholesterolaemia
- Focus Therapeutic Use
Most Recent Events
- 22 Jun 2020 New trial record
- 08 Jun 2020 Results published in the American Journal of Cardiovascular Drugs